Enhancing anticoagulation monitoring in patients undergoing maxillofacial surgery: a prospective observational trial

Recruiting

• Conditions: C02; C00-C14; Malignant neoplasm of other and unspecified parts of tongue; Malignant neoplasms of lip, oral cavity and pharynx

• Registration Number: DRKS00028193
• Lead Sponsor: niversitätsklinikum Carl Gustav CarusKlinik und Poliklinik für Anästhesie und Intensivmedizin

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-02-21
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

Adult patients above 18 years of age who are undergoing maxillofacial surgery and receive a microsurgical flap treatment. In detail the following cases are selected: cases: Patients who receive microvascular reconstruction as part of tumour surgery
- Patients who receive microvascular reconstruction as part of secondary reconstruction
- Patients who receive microvascular reconstruction in the context of bone necrosis or osteomyelitis

Exclusion Criteria

Patients developing severe coagulation disorder during in-hospital stay (DIC, HIT)
Patients with preexisting severe thrombophilia (anti-phospholipid-syndrome, homozygous FV-Leiden mutation, Anti-Thrombin defect)
Patients with preexisting severe bleeding disorder (Haemophilia A/B (residual activity <10%) and vWF-Syndrome Type 2B,M,N, 3)

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Primary endpoint is defined as free flap loss and the occurrence of flap thrombosis.

Secondary Outcome Measures

Name	Time	Method
Secondary outcomes are patients survival during in hospital stay and the incidence of any thromboembolic complication.